SciClone Pharmaceuticals (Holdings) Limited (HK:6600) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SciClone Pharmaceuticals (Holdings) Limited has announced that 12,500 Share Options from its Post-IPO Option Plan have lapsed as of June 15, 2024, according to the plan’s rules. Following this lapse, the company reports a total of 630,543,012 Shares in issue and 66,218,552 Share Options still in issue, comprised of different tranches under its Option Incentive and Post-IPO Option Plans.
For further insights into HK:6600 stock, check out TipRanks’ Stock Analysis page.